WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) reported strong interest in Quell coming out of last week’s Consumer Electronics Show (CES).
According to Frank McGillin, SVP and General Manager of Consumer Health at NeuroMetrix, “In the first several days that the QuellRelief.com website was live, we have had excellent traffic and an information request signup rate of over 20%. This exceeds our original expectations and reflects the need for a better solution for the over 100 million Americans living with chronic pain.”
In the past week, Quell was featured in original stories in well over 30 media outlets including, C|NET, Forbes, PC Magazine, Bloomberg, Drugstore News and MAC World. The new product was also selected as one of four finalist in the Engadget Best of CES 2015 Digital Health and Fitness category.
Quell is FDA cleared for treatment of chronic pain without a prescription. It uses NeuroMetrix's proprietary non-invasive neurostimulation technology to provide relief from chronic pain, such as due to diabetes, sciatica, fibromyalgia, and degenerative knee conditions. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. Users of the device will also have the option of using their smartphone to automatically track and personalize their pain therapy.
Consumers and medical professionals can visit QuellRelief.com to learn more and sign up to receive information. The company expects to begin taking pre-orders for Quell in March and to ship during the second quarter. Quell will initially be available exclusively through doctor’s office and online.
NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. For more information, please visit http://www.NeuroMetrix.com.